VC 004
Alternative Names: VC-004Latest Information Update: 09 Sep 2024
At a glance
- Originator Jiangsu Vcare Pharmatech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 26 Aug 2024 Jiangsu Vcare Pharmatech completes a phase I food effect and relative bioavailability trial in Healthy volunteers in China (PO, Capsule) (NCT06529445)
- 01 Aug 2024 Jiangsu Vcare Pharmatech plans a phase I food effect and relative bioavailability trial in Healthy volunteers in China (PO, Capsule) (NCT06529445)
- 22 Jul 2024 Jiangsu Vcare Pharmatech initiates a phase I food effect and relative bioavailability trial in Healthy volunteers in China (PO, Capsule) (NCT06529445)